NewsSource: EClinCloud

Webinar Recap | Applications of Electronic Document Management (eTMF) – Breaking with the Old to Build Anew

4 min readEClinCloud Editorial Team
Original video cover

Source: EClinCloud. Author: EClinCloud.

Article illustration

On June 17, 2022, the webinar "Success and Failure in Clinical Trials: Effective TMF Management for Facing Clinical Trial Inspections and Audits with Confidence," co-hosted by EClinCloud (Shenzhen) Technology Co., Ltd. (hereinafter "EClinCloud") and Tongxieyi, successfully concluded, attracting nearly 10,000 viewers.

 

The webinar featured three industry experts—Zeng Xiaoxia, Vice President of Product at EClinCloud; Yin Yuanyuan, Deputy General Manager and Medical Department Director at Kangzhe Biotechnology Co., Ltd.; and Han Juan, Co-founder of Shanghai Daoyi Pharmaceutical Technology Co., Ltd.—who shared their respective perspectives on current pain points and challenges in clinical trial TMF management, key points in domestic and international inspections, and how to build a digital TMF management system.


Click to view the webinar replay


Yin Yuanyuan, Deputy General Manager and Medical Department Director at Kangzhe Biotechnology Co., Ltd., noted that only with a sound quality management system can a project achieve reliable quality assurance across different stages. Although most companies' Trial Master File (TMF) indexes have evolved from the basic DIA index, significant differences still remain—much like the saying, "one mother bears nine children, and each is different." Particularly for sponsors that outsource different studies to different CROs, because each CRO uses a different document index, this creates oversight difficulties for the sponsor, reduces management efficiency, and may ultimately affect whether a product passes audits and inspections, or even its market approval.


Article illustration


Zeng Xiaoxia, Vice President of Product at EClinCloud, explained that regulatory authorities in every country review clinical trials of new drugs based on their respective national laws and regulations and internationally accepted clinical trial management practices, and require sponsors of new drugs to provide complete documentation demonstrating whether the clinical trial protected the rights and interests of subjects and generated scientific data. The TMF contains the primary essential documents of a clinical trial, collected by the sponsor and the investigator throughout the entire course of the trial; it must be able to reconstruct the clinical trial project to ensure the integrity of the trial, and it also serves as a critical component of the "evidence." Therefore, without TMF records as proof, there is no evidence to substantiate the clinical trial procedures. When regulatory authorities conduct audits and inspections, they also typically begin with the TMF documents, so managing TMF documentation effectively has a direct bearing on the success or failure of a clinical trial.


Article illustration


Han Juan, Co-founder of Shanghai Daoyi Pharmaceutical Technology Co., Ltd., stated that relatively common findings in TMF audits and inspections include: failure to establish a TMF management process or a study-specific TMF management plan; incomplete TMF filing, misfiling, duplicate filing, or an unclear document structure and index (such as confusing indexing); and a lack of effective end-to-end quality control (QC) over the TMF, among others. Han Juan noted that the TMF is in fact a record of the entire clinical trial process, and by reviewing the records in the TMF, the observations and conclusions of the trial can be reconstructed. Likewise, documented records serve as evidence of data authenticity and integrity, and teams must remember to maintain Inspection Readiness at all times.


Article illustration


As clinical trials are conducted globally, organizing the TMF has become increasingly complex. To do good work, one must first have the right tools. Benefiting from the steady advancement of digital technology, an electronic TMF—eTMF—is a better choice. As paper submissions transition toward electronic regulatory submissions, electronic Trial Master File (eTMF) management systems have also become the most widely used clinical research information systems after EDC and CTMS.



EClinCloud's Technical Solution for TMF Management


Establishing a secure data management system to keep clinical research activities organized and compliant with regulatory requirements further helps pharmaceutical companies gain market access.

 

EClinCloud's eTMF is a system that helps pharmaceutical companies and sponsors manage their TMF effectively.


Article illustration


Click the image below

View EClinCloud eTMF product details

☟ ☟ ☟

Article illustration


About EClinCloud


EClinCloud is a healthcare and life sciences technology company based in China and serving clients worldwide. Guided by the mission of "bringing effective treatments to patients through technological innovation" and driven by science and medicine, it combines digital technology with life sciences data to build an end-to-end digital clinical trial cloud platform and provide technical solutions for clinical endpoint assessment, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.



Article illustration

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.